Inhibikase Therapeutics (IKT) director Berman received 70,106 Stock Option (Right to Buy)

Insider transactions reported

Dennis N Berman (director at Inhibikase Therapeutics Inc., IKT) reported that they received 70,106 Stock Option (Right to Buy), and returned to the company 70,106 Stock Option (Right to Buy) on Jan 21, 2025.

Reporting person

Berman Dennis N

Options and other derivatives

Holdings before and after

• Stock Option (Right to Buy): 21,854 to 30,000 indirect, By Molino Ventures, LLC

Footnotes from the filing

1. 1. The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.
2. 2. The transactions reported herein reflect an option repricing (the Repricing ) effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
3. 3. This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
4. 4. The acquisition of the reported option was reported in a Form 4 filed on December 29, 2020, which mistakenly reported the expiration date as December 22, 2030.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

Sale back to the company:

Code D marks a disposition back to the company under an exempt plan, as opposed to a sale in the market.

FAQ